Gene Seen to Protect Motor Neurons May Serve as ALS and SMA Therapy, Study Suggests
The protein synaptotagmin 13 (SYT13) protected motor neurons from degeneration in cell and animal models of amyotrophic lateral…
Articles by Marisa Wexler, MS
ALS Telecare App Benefits Patients, Providers, Study Shows
People with amyotrophic lateral sclerosis (ALS) may benefit from at-home monitoring using an app, a study found. The study,…
Potential Protein Target for Antibody Therapy Identified in Early Study
Antibodies that target proteins wrongly expressed in the brain and driven by mutations in C9ORF72, a cause of amyotrophic…
Study Links Cognitive Impairment with Toxic Protein Clumps in ALS
Cognitive impairment in amyotrophic lateral sclerosis (ALS) may be linked to the buildup of the protein TDP-43 in…
ALS Research Ambassador Collaboration Enabled More Patient-centered Design of REFINE-ALS Trial
Including ALS Research Ambassadors — a group of amyotrophic lateral sclerosis (ALS) patients and their caregivers — in discussions about…
Insurance Data May Predict ALS, Research Shows
A machine-learning model based on insurance information from amyotrophic lateral sclerosis (ALS) patients may be able to speed diagnosis…
Soleo and Mitsubishi Tanabe Enter Data-sharing Agreement for Radicava
Mitsubishi Tanabe Pharma America (MTPA) and Soleo Health have entered into an agreement that will facilitate Soleo sharing…
Ibudilast Most Effective in People with Short History of ALS, Analysis Suggests
MediciNova‘s experimental therapeutic ibudilast (MN-166) may be most effective for treating amyotrophic lateral sclerosis (ALS)…
Exservan, Riluzole in Dissolving Oral Film Form, Approved by FDA
A dissolving oral film form of riluzole, called Exservan and able to be taken by amyotrophic lateral sclerosis (ALS)…
Phase 2 Trial Data on NurOwn Therapy, Supporting Safety And Early Efficacy, Published
NurOwn showed a good safety profile, as well as potential efficacy in a Phase 2 clinical trial that included people…